1. Bae JM, Won YJ, Jung KW, Park JG. Annual report of the Central Cancer Registry in Korea-2000: based on registered data from 131 hospitals. Cancer Res Treat. 2002; 34:77–83.
2. Rowinsky EK, Kaufmann SH. Topotecan in combination chemotherapy. Semin Oncol. 1997; 24(6):Suppl 20. S20-11–S20-26.
3. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, et al. An early phase II study of CPT-11: a new derivative of camptothecin for the treatment of leukemia and lymphoma. J Clin Oncol. 1990; 8:1907–1912. PMID:
2230878.
Article
4. Masuda N, Fukuoka M, Kusunoki Y, Mtsui K, Takifuji N, Kudoh S, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992; 10:1225–1229. PMID:
1321891.
Article
5. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. A phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small cell lung cancer. J Clin Oncol. 1992; 10:16–20. PMID:
1309380.
6. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol. 1993; 11:909–913. PMID:
8487053.
7. Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY, et al. Antitumor Activity of 7-[2-(N-Isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a Potent DNA Topoisomerase I inhibitor. Arch Pharm Res. 1998; 21:581–590. PMID:
9875499.
Article
8. Kim HK, Bang YJ, Heo DS, Shin SG, Kim NK. Phase I trial of CKD-602, a novel camptothecin derivative, in patients with advanced solid tumors. Proc Am Soc Clin Oncol. 2002; 21:(abstr 393).
9. Song Y, Seo SS, Bang YJ, Kang SB, Nam JH, Ryu SY, et al. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule in patients with recurrent or refractory ovarian cancer. Proc Am Soc Clin Oncol. 2003; 22:(abstr 1877).
10. Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter G, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol. 1997; 41(4):307–316. PMID:
9488600.
Article
11. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, et al. Synergism between cisplatin and topoisomerase inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res. 1996; 56:789–793. PMID:
8631015.
12. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 1992; 50:604–610. PMID:
1537625.
Article
13. Bungo M, Fujiwara Y, Kasahara K, Nakagawa K, Ohe Y, Sasaki Y, et al. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum (II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res. 1990; 50:2549–2553. PMID:
2158392.
14. Liu LF, Miller KG. Eukaryotic DNA topoisomerase: two forms of type I DNA topoisomerase from HeLa cell nuclei. Proc Natl Acad Sci USA. 1981; 78:3487–3491. PMID:
6267594.
15. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Xunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol. 1998; 41:383–390.
Article
16. Fichtinger-Schepman AMJ, van der Veer JL, den Hartog JH, Lohman PHM, Reedijk J. Adducts of the antitumor drug cisdiamminedichloroplatinum( II) with DNA: formation, identification, and quantitation. Biochmistry. 1985; 24:707–713.
17. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem. 1994; 269:787–790. PMID:
8288625.
Article
18. Swinnen LJ, Ellis NK, Erickson LC. Inhibition of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II)-induced DNA interstrand cross-link removal and potentiation of cis-diammine-1,1-cyclobutane dicarboxyl-atoplatinum(II) cytotoxicity by hydroxyurea and 1β-D-arabinofuranosylcytosine. Cancer Res. 1991; 51:1984–1989. PMID:
2009517.
19. Esaki T, Nakano S, Tatsumoto T, Kuroki-Migita M, Mitsugi K, Nakamura M, et al. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum( II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res. 1992; 52:6501–6506. PMID:
1423296.
20. Eastman A, Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry. 1988; 27:4730–4734. PMID:
3167012.
Article
21. Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enchanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest. 1991; 87:772–777. PMID:
1999494.
22. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relaxation to antitumor activity. Cancer Res. 1989; 49:1465–1469. PMID:
2538227.
23. Bellon SF, Coleman JH, Lippard SJ. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry. 1991; 30:8026–8035. PMID:
1868076.
Article
24. van Waardenburg RC, de Jong LA, van Eijndhoven MA, Verseyden C, Pluim D, Jansen LE, et al. Plainated DNA Adducts Enhance Poisoning of DNA Topoisomerase I by Camptothecin. J Biol Chem. 2004; 279:54502–54509. PMID:
15471886.
25. Park JG, Yang HK, Kim WH, Chung JK, Kang MS, Lee JH, et al. Establishment and characterization of human gastric carcinoma cell lines. Int J Cancer. 1997; 70:443–449. PMID:
9033653.
Article